Anja Slikkerveer (MD PhD ERT) is a pragmatic drug development professional with over 30 years’ experience in nonclinical drug development. Being a physician (MD) and a toxicologist, she is very well equipped to work in translational science and assess potential clinical (side) effects. ​

In her career, Anja has championed the transition of numerous drugs from preclinical to phase 1 and participated in many scientific advice meetings with EMA and local authorities, and prepared Marketing Applications (MAA/NDA).  Anja has been involved in all aspects of drug development, including designing and executing nonclinical drug development program’s (phase 0 to phase 4), Environmental Risk Assessment reports (ERA’s) and has submitted over 20 MAA’s.  ​

She has a special interest in the safety assessment for drug substances and products, (solvents, [elemental] impurities, assessments of cleaning limits) as she was an EFPIA topic expert in the ICH Q3D Expert working Group. ​